Previous 10 | Next 10 |
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Bioph...
2024-02-15 18:38:05 ET Three otherwise innocuous words -- reverse stock split -- can cause much disappointment and even sow panic in an investor community. Shareholders of clinical-stage biotech Agenus (NASDAQ: AGEN) experienced this vividly on Thursday when their company announced ...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 62.5% to $3.665 on volume of 269,509,234 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 64.1% to $0.105 on volume of 159,463,786 shares Sientra Inc. (SIEN) rose 119.4% to $0.395 on volume of...
2024-02-15 13:58:40 ET More on Agenus, Ginkgo Bioworks, etc. Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment Agenus: Taking Advantage Of The Risk-Reward Opportunity Agenus: 2024 May Finally Be The Year For A Major Turnaroun...
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design PR Newswire BOSTON and LEXINGTON, Mass. , Feb. 15, 2024 /PRNewswire/ -- The Defense Threat Reduction Agency...
2024-02-09 12:14:22 ET More on Moderna Moderna: Fade 2025 Outlook Moderna's Post-Covid Hangover Might Persist For A Few More Years Moderna, Inc. (MRNA) JPMorgan 42nd Annual Healthcare Conference Transcript Moderna RSV vaccine lags rival shots in long-term eff...
2024-02-08 15:32:06 ET More on GSK, Moderna, etc. Pfizer: The 6.3% Yield Is A Appealing Pfizer: Simply Too Cheap To Ignore Pfizer Is Down 54% From Highs, Now Yields 6.1% GSK stock traded in green for seventh straight session GSK RSV vaccine under FDA ...
2024-02-06 08:46:40 ET More on GSK GSK plc (GSK) Q4 2023 Earnings Call Transcript GSK plc 2023 Q4 - Results - Earnings Call Presentation GSK: Robust Earnings Report Expected, 2024 Outlook Is Key GSK blood cancer therapy nearly triples survival in late stage t...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthca...
2024-01-30 12:20:27 ET More on GSK GSK: Robust Earnings Report Expected, 2024 Outlook Is Key GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript) AbbVie Vs. GSK: Dual Dominance In Pharma GSK enters licensing deal with Elegen Watch GS...
News, Short Squeeze, Breakout and More Instantly...
2024-04-28 08:30:00 ET Last Friday, Agenus (NASDAQ: AGEN) , an immuno-oncology player, saw its shares soar by a staggering 40.8%. This remarkable rally occurred seemingly without a clear catalyst. The company is set to announce its first-quarter earnings for 2024 before the market o...
A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 20.6% to $0.0626 on volume of 316,091,551 shares Snap Inc. Class A (SNAP) rose 27.6% to $14.55 on volume of 158,621,648 shares PROSHARES TRUST (SQQQ) fell 4.8% to $11.43 on volume of 135,432,504 share...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab (“BOT/BAL”) in patients with relapsed/ref...